Risk of Arrhythmia Among New Users of Hydroxychloroquine in Rheumatoid Arthritis and Systemic Lupus Erythematosus: A Population‐Based Study

We assessed the association between hydroxychloroquine (HCQ) initiation and risk of arrhythmia among patients with incident rheumatoid arthritis (RA) or with incident systemic lupus erythematosus (SLE).

[1]  M. Link,et al.  American College of Rheumatology White Paper on Antimalarial Cardiac Toxicity , 2021, Arthritis & rheumatology.

[2]  M. Wasko,et al.  Association of Hydroxychloroquine Use With Decreased Incident Atrial Fibrillation in Systemic Lupus Erythematosus , 2021 .

[3]  Yu-Hsun Wang,et al.  Association of hydroxychloroquine and cardiac arrhythmia in patients with systemic lupus erythematosus: A population-based case control study , 2021, PloS one.

[4]  Douglas F. Redd,et al.  Cardiovascular Safety of Hydroxychloroquine in US Veterans With Rheumatoid Arthritis , 2021, Arthritis & rheumatology.

[5]  J. Esdaile,et al.  Impact of Antimalarial Adherence on Mortality Among Patients With Newly Diagnosed Systemic Lupus Erythematosus: A Population‐Based Cohort Study , 2021, Arthritis care & research.

[6]  Hyon K. Choi,et al.  Hydroxychloroquine and Mortality Among Patients With Systemic Lupus Erythematosus in the General Population , 2020, Arthritis care & research.

[7]  L. Epstein,et al.  Effect of Chloroquine, Hydroxychloroquine, and Azithromycin on the Corrected QT Interval in Patients With SARS-CoV-2 Infection , 2020, Circulation. Arrhythmia and electrophysiology.

[8]  A. Nabar,et al.  Cardiovascular risks of hydroxychloroquine in treatment and prophylaxis of COVID-19 patients: A scientific statement from the Indian Heart Rhythm Society , 2020, Indian Pacing and Electrophysiology Journal.

[9]  S. Drăgan,et al.  Heart Involvement in Inflammatory Rheumatic Diseases: A Systematic Literature Review , 2019, Medicina.

[10]  D. Gladman,et al.  Severe brady-arrhythmias in systemic lupus erythematosus: prevalence, etiology and associated factors , 2018, Lupus.

[11]  Tyler J. VanderWeele,et al.  Sensitivity Analysis in Observational Research: Introducing the E-Value , 2017, Annals of Internal Medicine.

[12]  A. López-Candales,et al.  Linking Chronic Inflammation with Cardiovascular Disease: From Normal Aging to the Metabolic Syndrome. , 2017, Journal of nature and science.

[13]  E. Campos,et al.  Hydroxychloroquine for treatment of rheumatoid arthritis: multifocal electroretinogram and laser flare-cell photometry study , 2017, Clinical ophthalmology.

[14]  M. Abrahamowicz,et al.  Improvement in 5-year mortality in incident rheumatoid arthritis compared with the general population—closing the mortality gap , 2016, Annals of the rheumatic diseases.

[15]  Jason P. Fine,et al.  Statistical Primer for Cardiovascular Research Introduction to the Analysis of Survival Data in the Presence of Competing Risks , 2022 .

[16]  L. Rönnblom,et al.  Case definitions in Swedish register data to identify systemic lupus erythematosus , 2016, BMJ Open.

[17]  Hyon K. Choi,et al.  Statin use and mortality in rheumatoid arthritis: a general population-based cohort study , 2015, Annals of the rheumatic diseases.

[18]  J. Ramires,et al.  Evidence for cardiac safety and antiarrhythmic potential of chloroquine in systemic lupus erythematosus. , 2014, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[19]  Douglas P Kiel,et al.  Competing Risk of Death: An Important Consideration in Studies of Older Adults , 2010, Journal of the American Geriatrics Society.

[20]  M. Miller.  Agency , 2010 .

[21]  S. Cole,et al.  Competing risk regression models for epidemiologic data. , 2009, American journal of epidemiology.

[22]  Dawn Peters,et al.  Determinants of Prolonged QT Interval and Their Contribution to Sudden Death Risk in Coronary Artery Disease: The Oregon Sudden Unexpected Death Study , 2009, Circulation.

[23]  M. Roman,et al.  Subclinical atherosclerosis in rheumatoid arthritis and systemic lupus erythematosus. , 2008, The American journal of medicine.

[24]  P. Seferovic,et al.  Cardiac arrhythmias and conduction disturbances in autoimmune rheumatic diseases. , 2006, Rheumatology.

[25]  A. M. Walker,et al.  An application of propensity score matching using claims data , 2005, Pharmacoepidemiology and drug safety.

[26]  K. Pramatarov.  Drug-induced lupus erythematosus. , 1998, Clinics in dermatology.

[27]  E. Tsakonas,et al.  A Long-Term Study of Hydroxychloroquine Withdrawal on Exacerbations in Systemic Lupus Erythematosus , 1998 .

[28]  R. Marrie,et al.  Persistence and adherence to the new oral disease-modifying therapies for multiple sclerosis: A population-based study. , 2019, Multiple sclerosis and related disorders.

[29]  J. Esdaile,et al.  Antimalarial Medications , 2019, Dubois' Lupus Erythematosus and Related Syndromes.

[30]  E. Bonfá,et al.  Arrhythmias in systemic lupus erythematosus. , 2010, Revista brasileira de reumatologia.

[31]  M. Petri,et al.  Hydroxychloroquine use in the Baltimore Lupus Cohort: effects on lipids, glucose and thrombosis. , 1996, Lupus.

[32]  R. Gray.  A Class of $K$-Sample Tests for Comparing the Cumulative Incidence of a Competing Risk , 1988 .

[33]  T. Bolin,et al.  OF HEALTH , 2022 .